Gilead's recent disaster in oncology clinical trials ( patients dying), has prompted new CEO John Milligan to highlight other possible acquisition targets - inflammatory diseases and liver diseases. Two of Gilead's drugs raked in almost 5 billion dollars 4th quarter last year. One of those drugs for Hep C, Sovaldi was picked up for only 11 million in 2011. Barbarian, your friend maybe right, but there is too much upside to be selling on rumour at .009 cents.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
0.003(3.19%) |
Mkt cap ! $8.232M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.7¢ | $3.425K | 34.93K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5200 | 9.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 244080 | 3 |
View Market Depth
| Last trade - 15.55pm 25/07/2025 (20 minute delay) ? |
| IVX (ASX) Chart |